Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Evaxion Biotech ( (EVAX) ).
Evaxion Biotech A/S has announced an amendment to the effective date for changing the ratio of its American Depositary Shares (ADSs) from one ADS representing ten ordinary shares to one ADS representing fifty ordinary shares, now set for January 14, 2025. This change is expected to enhance liquidity and potentially increase the trading price of the ADSs, though there is no guarantee of proportional price movement.
More about Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage TechBio company based in Copenhagen, Denmark, focusing on the development of AI-powered vaccines through its proprietary AI-Immunology platform. The company aims to innovate immunotherapies for cancer, bacterial diseases, and viral infections, with a clinical-stage oncology pipeline and preclinical infectious disease pipeline addressing high unmet medical needs.
YTD Price Performance: -3.26%
Average Trading Volume: 347,273
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.82M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.
